Glypinor 500 ER
Sitagliptin plus extended-release metformin for comprehensive, low-hypoglycaemia-risk glycaemic control.
“Balanced sugar control. Lower risk. Better compliance.”
Composition
- Active ingredients
- Sitagliptin 50 mg + Metformin (Extended-Release) 500 mg
- Dosage form
- Extended-release tablets
- Pack size
- 10x3 tablets
Indications
- Type 2 Diabetes Mellitus
- Inadequate control on metformin alone
- Elderly or high hypoglycaemia-risk patients
Dosage snapshot
- Sitagliptin
- 50 mg once daily
- Metformin ER
- 500 mg once daily, titrate as needed
- Maximum metformin dose
- 2000 mg per day
Dosage should be individualised by the prescribing physician.
Key benefits
- Dual mechanism enhances insulin response while reducing hepatic glucose output.
- Controls post-prandial (post-meal) glucose spikes.
- Low hypoglycaemia risk, making it suitable for elderly and long-term use.
- Extended-release form reduces gastrointestinal side effects.
Why this formula works
Glypinor 500 ER combines a DPP-4 inhibitor with extended-release metformin so the two agents work on complementary pathways: sitagliptin enhances the body's own incretin-mediated insulin response, particularly after meals, while metformin ER reduces hepatic glucose output.
Because DPP-4 inhibitors carry an inherently low risk of hypoglycaemia, this combination is positioned for patients — including elderly patients — who need dependable glycaemic control without the added burden of hypoglycaemia risk, with the extended-release metformin format chosen to improve gastrointestinal tolerability.